Skip to main content
    S

    Scinai Immunotherapeutics Ltd (SCNI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.40
    -0.04 (-9.50%)

    Market Cap: $1.05M

    Last updated: Nov 17, 2026 at 10:54 AM ET

    Scinai Immunotherapeutics Ltd (SCNI) Earnings: Report Dates and Results

    Updated Jul 7, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Jun 30, 2026, Scinai Immunotherapeutics reported EPS of -$0.74. It beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    40%(8/20)
    Avg Surprise
    -27.10%

    Next Report

    SCNI's next report is not on the earnings calendar yet.

    SCNI Earnings Call

    The latest SCNI earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    Earnings History

    Of the 21 quarters below that had an estimate, SCNI beat 9 and missed 12. Revenue for the quarter ended Jun 30, 2026 was $467898, up 21.1% from $386500 a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Jun 30, 2026-$0.74N/AN/AN/AN/AN/AN/AN/AJul 7, 2026$467898
    Mar 31, 2026$0.94N/AN/AN/AN/A-78.2%N/AN/AJun 10, 2026$487674
    Sep 30, 2025-$24.85N/AN/AN/AN/A-300.6%N/AN/ADec 2, 2025$269000
    Jun 30, 2025-$2.60N/AN/AN/AN/AN/AN/AN/ASep 2, 2025$386500
    Mar 31, 2025$4.31N/AN/AN/AN/AN/AN/AN/AMay 7, 2025$586000
    Dec 31, 2024-$26.35N/AN/AN/AN/AN/AN/AN/AFeb 26, 2025$206000
    Sep 30, 2024$12.39N/AN/AN/AN/A+54.9%N/AN/ANov 22, 2024$168000
    Jun 30, 2024-$4.31N/AN/AN/AN/AN/AN/A0 up, 0 downJul 2, 2024$284000
    Mar 31, 2024-$24.00-$6.20N/A-287.10%MissN/AN/A0 up, 0 downMay 15, 2024N/A
    Dec 31, 2023-$240.00-$62.00N/A-287.10%MissN/AN/A0 up, 0 downDec 31, 2023N/A
    Sep 30, 2023$8.00-$9.40N/A+185.11%Beat+2658.6%10 up, 0 downOct 31, 2023N/A
    Jun 30, 2023-$12.00-$9.10N/A-31.87%MissN/AN/AN/AAug 11, 2023N/A
    Mar 31, 2023-$12.00-$7.30N/A-64.38%MissN/AN/AN/AApr 17, 2023N/A
    Sep 30, 2022$0.29-$1.00N/A+129.00%BeatN/AN/AN/ANov 30, 2022N/A
    Jun 30, 2022-$0.61-$1.00N/A+39.00%BeatN/AN/AN/AAug 25, 2022N/A
    Mar 31, 2022-$23.93-$10.00N/A-139.30%MissN/AN/AN/AJun 1, 2022N/A
    Dec 31, 2021$0.01-$0.16N/A+106.25%Beat-99.7%N/AN/AMar 31, 2022N/A
    Sep 30, 2021-$0.01N/AN/AN/AN/A-172.4%N/AN/ANov 30, 2021N/A
    Jun 30, 2021-$0.01N/AN/AN/AN/AN/AN/AN/AAug 26, 2021N/A
    Mar 31, 2021-$1.14-$1.00N/A-14.00%MissN/AN/AN/AMay 13, 2021N/A
    Dec 31, 2020$3.05-$1.00N/A+405.00%BeatN/AN/AN/AMar 31, 2021N/A
    Sep 30, 2020$0.01N/AN/AN/AN/AN/AN/AN/ASep 30, 2020N/A
    Jun 30, 2020-$0.10-$0.10N/A0.00%MissN/AN/AN/AAug 20, 2020N/A
    Mar 31, 2020-$2.87-$1.00N/A-187.00%MissN/AN/AN/AJun 12, 2020N/A
    Dec 31, 2019-$0.01N/AN/AN/AN/AN/AN/AN/ADec 31, 2019N/A
    Sep 30, 2019-$1.44-$2.00N/A+28.00%BeatN/AN/AN/ANov 26, 2019N/A
    Jun 30, 2019-$5.10-$2.00N/A-155.00%MissN/AN/AN/AAug 28, 2019N/A
    Mar 31, 2019-$3.89-$1.00N/A-289.00%MissN/AN/AN/AApr 30, 2019N/A
    Dec 31, 2018-$0.01N/AN/AN/AN/AN/AN/AN/ADec 31, 2018N/A
    Sep 30, 2018-$0.27-$1.00N/A+73.00%Beat-102.4%N/AN/ANov 13, 2018N/A
    Jun 30, 2018-$0.03-$0.01N/A-175.00%MissN/AN/AN/AAug 22, 2018N/A
    Mar 31, 2018-$1.39N/AN/AN/AN/AN/AN/AN/AMay 29, 2018N/A
    Dec 31, 2017-$0.02N/AN/AN/AN/AN/AN/AN/AMar 31, 2018N/A
    Sep 30, 2017$11.43-$9.50N/A+220.32%Beat+219707.7%N/AN/ANov 28, 2017N/A
    Jun 30, 2017-$78.06N/AN/AN/AN/AN/AN/AN/AAug 31, 2017N/A
    Mar 31, 2017-$0.02-$0.01N/A-98.00%MissN/AN/AN/AMay 30, 2017N/A
    Dec 31, 2016$0.00N/AN/AN/AN/AN/AN/AN/ADec 31, 2016N/A
    Sep 30, 2016$0.01-$0.01N/A+152.00%Beat-99.5%N/AN/ANov 28, 2016N/A
    Jun 30, 2016-$0.21-$0.01N/AN/AN/AN/AN/AN/AAug 22, 2016N/A
    Mar 31, 2016-$135.86N/AN/AN/AN/AN/AN/AN/AJun 1, 2016N/A
    Last 40 quarters

    Estimates made before a stock split are shown on the same share basis as the reported EPS.

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$3.60, after -$42.27 the year before. It was -$549.48 for the year ended Dec 31, 2017, the oldest of the 7 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$3.60N/A
    Dec 31, 2024-$42.27N/A
    Dec 31, 2023-$280.25N/A
    Dec 31, 2022-$30.80N/A
    Dec 31, 2021-$1.15N/A
    Dec 31, 2020-$12.04N/A
    Dec 31, 2017-$549.48N/A

    Earnings Calls

    The only earnings call listed below, 2026Q2 for the period ended Jun 30, 2026, runs about 3,000 words across 2 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q2Jun 30, 20263,0112

    2026Q2 Earnings Call

    Opening remarks

    Andrew Eriksen Moderator / Managing Director, Allele Capital All right. I think we're live now, so let's jump in. Thank you, everyone, for joining today, Scinai Immunotherapeutics corporate overview and 2026 midyear business update. My name is Andrew Eriksen. I'm a Managing Director here at Allele Capital, who works directly with the Scinai team, and we're helping put on this event today. We're going to run through a bit of the first half results that you might have noticed Scinai published just yesterday, review some of those financials, some of those business updates, and then Amir is going to give us a bit of an outlook for the rest of 2026 and why the team is ultimately really excited about what's to come. So without further ado, we'll get into it, and then we'll save the questions at the end. If you're watching on LinkedIn or YouTube, there's chat boxes for both of those platforms, so submit your questions, and we'll get to those at the end of the conversation. Without further ado, let's jump into the call here, Amir. Maybe what you can do is, I'm sure a lot of people on the call are familiar with who you are, but maybe just a quick background on yourself and your role at Scinai and then we can get into some of the first half details.

    Amir Reichman Chief Executive Officer (CEO), Scinai Immunotherapeutics Thank you very much, Andrew, and welcome, everybody, to our webinar today. I'm Amir Reichman. I have a master's degree in biotechnology engineering and an MBA from the Wharton School of the University of Pennsylvania. My background goes back more than 20 years in the pharmaceutical industry across the United States, Europe and Israel. Now I'm leading Scinai as the CEO of Scinai Immunotherapeutics, the parent company, and also of the subsidiary, Scinai Biopharma Services, our CDMO subsidiary.

    Andrew Eriksen Moderator / Managing Director, Allele Capital With that, let's jump in. As we discussed, the first half results got published yesterday, and I think there were a lot of positives coming out of that. But before we get into the individual numbers, can you put the first half of 2026 into perspective for investors, Amir? What changed at Scinai? Where does the company stand today versus the beginning of the year?

    Amir Reichman Chief Executive Officer (CEO), Scinai Immunotherapeutics Thank you, Andrew. Time flies. The most important way to look at the first half of 2026 is that Scinai today is a materially different company than the one that entered the year. At the beginning of 2026, we had our innovative immunology R&D pipeline and an emerging CDMO business in Jerusalem. During the first half, we significantly expanded the commercial side of the company through the acquisition of the former Recipharm operations in Yavne, Israel.

    Frequently Asked Questions About SCNI

    How often does SCNI beat earnings estimates?

    Scinai Immunotherapeutics beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate, with an average surprise of -57.08%.